Cargando…
Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer
SIMPLE SUMMARY: To date, the therapeutic strategy and guidelines in small cell lung cancer (SCLC) are based on cancer cell-related attributes with no biomarker used in the clinical practice. In the present study, using RNAseq and IHC, we aim to characterize in the frontline the latest biomarkers of...
Autores principales: | Dora, David, Rivard, Christopher, Yu, Hui, Pickard, Shivaun Lueke, Laszlo, Viktoria, Harko, Tunde, Megyesfalvi, Zsolt, Dinya, Elek, Gerdan, Csongor, Szegvari, Gabor, Hirsch, Fred R., Dome, Balazs, Lohinai, Zoltan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228874/ https://www.ncbi.nlm.nih.gov/pubmed/34200100 http://dx.doi.org/10.3390/biology10060502 |
Ejemplares similares
-
Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
por: Dora, David, et al.
Publicado: (2020) -
EZCancerTarget: an open-access drug repurposing and data-collection tool to enhance target validation and optimize international research efforts against highly progressive cancers
por: Dora, David, et al.
Publicado: (2022) -
Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC)
por: Lohinai, Zoltan, et al.
Publicado: (2019) -
Effective Reversal of Macrophage Polarization by Inhibitory Combinations Predicted by a Boolean Protein–Protein Interaction Model
por: Szegvari, Gabor, et al.
Publicado: (2023) -
PD-1 and PD-L1 expression in rare lung tumors
por: Gyulai, Marton, et al.
Publicado: (2023)